Roth/MKM Starts vTv Therapeutics (VTVT) at Buy

Roth/MKM analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a price target of $58.00.

The analyst comments "Initiating coverage of vTv Therapeutics with Buy rating and $58 PT. We believe cadisegliatin (cadi) is positioned to become the first approved oral adjunct for type 1 diabetes (T1D), addressing why 80% of adults fail to reach ADA A1C goal <7%. Our KOL consultant is bullish and expects approval with broad adoption if the Phase 3 program replicates. vTv owns major-market rights with patents through 2041. We forecast ~$1.5B unadjusted 2035 peak sales, with Phase 3 CATT1 data by YE 2026 as a significant catalyst. 3Q25 cash of $98M covers CATT1 results by our estimate."

For an analyst ratings summary and ratings history on vTv Therapeutics click here. For more ratings news on vTv Therapeutics click here.

Shares of vTv Therapeutics closed at $33.05 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)